SOURCE-LINKED STUDY SUMMARY
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Full paper summarizedQuality not appraised
- What was studied
- This full-text narrative review and secondary analysis synthesized preclinical work, phase 2 data, and the SURPASS 1-5 trials of tirzepatide for type 2 diabetes.
- Who / model studied
- The six summarized clinical trials enrolled adults with type 2 diabetes and ran for 26 to 104 weeks, using placebo, semaglutide, dulaglutide, or basal insulin comparators.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Across SURPASS 1-5, tirzepatide reduced HbA1c by 1.69 to 2.58% and body weight by 5.4 to 11.7 kg. Nausea, vomiting, diarrhea, and constipation were the main adverse events.
- Limitations & context
- This was a review, not one randomized trial. Cardiovascular analyses had few events, and the added contribution of GIP-receptor agonism remained uncertain.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1186/s12933-022-01604-7